Ocular Therapeutix OCUL Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ocular Therapeutix's business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ocular Therapeutix's business segments — allocated share based compensation expense?
- Ocular Therapeutix (OCUL) reported business segments — allocated share based compensation expense of $15.58M in Q1 2026.
- How has Ocular Therapeutix's business segments — allocated share based compensation expense changed year-over-year?
- Ocular Therapeutix's business segments — allocated share based compensation expense increased by 49.0% year-over-year, from $10.46M to $15.58M.
- What is the long-term trend for Ocular Therapeutix's business segments — allocated share based compensation expense?
- Over 3 years (2022 to 2025), Ocular Therapeutix's business segments — allocated share based compensation expense has grown at a 36.5% compound annual growth rate (CAGR), from -$16.96M to $43.18M.
- What does business segments — allocated share based compensation expense mean?
- This represents the non-cash expense recognized for equity-based awards granted to employees and contractors within the business segment. It is a critical component for understanding the total cost of talent and the dilutive impact of compensation strategies.